Pulmonx Corp (LUNG) is a Healthcare · Medical Devices company listed on NASDAQ. Price $2.07 (+4.55%), Market cap $0.05B, 52-week low–high $1.17 ~ $3.78.
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It offers Zephyr Endobronchial Valve; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also offers LungTraX Platform, a cloud-based quantitative computed tomography analysis service that provides physicians with multiple products, such as LungTraX Connect to improve workup efficiency; LungTraX Detect to enable patient identification; and StratX Lung report that is
Financial statements, price targets, institutional (13F) holdings and related news for Pulmonx Corp are updated in real time on BlackAll Trade.
Pulmonx Corp trades at $2.07 (+4.55%). Real-time quotes and charts are available on BlackAll Trade.
Pulmonx Corp has a market cap of about $0.05B.
Pulmonx Corporation, a commercial-stage medical technology company that provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease. It